A

Menaquinone-7 Supplementation Improves Osteogenesis in Pluripotent Stem Cell Derived Mesenchymal Stem Cells

Frontiers in Cell and Developmental Biology, vol. 8, pp. 618760

Abstract

Development of clinical stem cell interventions are hampered by immature cell progeny under current protocols. Human mesenchymal stem cells (hMSCs) are characterized by their ability to self-renew and differentiate into multiple lineages. Generating hMSCs from pluripotent stem cells (iPSCs) is an attractive avenue for cost-efficient and scalable production of cellular material. In this study we generate mature osteoblasts from iPSCs using a stable expandable MSC intermediate, refining established protocols. We investigated the timeframe and phenotype of cells under osteogenic conditions as well as the effect of menaquinone-7 (MK-7) on differentiation. From day 2 we noted a significant increase in RUNX2 expression under osteogenic conditions with MK-7, as well as decreases in ROS species production, increased cellular migration and changes to dynamics of collagen deposition when compared to differentiated cells that were not treated with MK-7. At day 21 OsteoMK-7 increased alkaline phosphatase activity and collagen deposition, as well as downregulated RUNX2 expression, suggesting to a mature cellular phenotype. Throughout we note no changes to expression of osteocalcin suggesting a non-canonical function of MK-7 in osteoblast differentiation. Together our data provide further mechanistic insight between basic and clinical studies on extrahepatic activity of MK-7. Our findings show that MK-7 promotes osteoblast maturation thereby increasing osteogenic differentiation.

Authors 7

  1. Maastricht University

    Affiliation as printed

    Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands

  2. Maastricht University · Nattopharma (Norway)

    Affiliation as printed

    Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands

    NattoPharma ASA, Oslo, Norway

  3. Maastricht University

    Affiliation as printed

    Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands

  4. University of Bonn · University Hospital Bonn

    Affiliation as printed

    Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany

  5. University of Bonn · University Hospital Bonn

    Affiliation as printed

    Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany

  6. University of Bonn · University Hospital Bonn

    Affiliation as printed

    Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany

  7. Maastricht University · RWTH Aachen University

    Affiliation as printed

    Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands

    Department of Nephro-Cardiology, Rheinisch-Westfälische Technische Hochschule Klinikum, Aachen, Germany

Cited by 17 stored of 17

17 results

No patents citing this paper on Lens.org (checked 2026-10-06).

References 48